Laquinimod therapy in multiple sclerosis: a comprehensive review.

ABSTRACT:

Introduction

Multiple sclerosis (MS) is considered an autoimmune disease with inflammatory and neurodegenerative underlying processes that affect the central nervous system. The available disease-modifying therapies (DMTs) approved to treat MS have only shown partial benefit in controlling the disease progression, primarily impeding its inflammatory component, while the parenteral administration of most of these therapies has shown to affect patient compliance. Laquinimod is a promising new oral drug recently evaluated in a third phase III clinical trial that demonstrated beneficial effects in delaying disease progression and preventing brain atrophy, suggesting a potential neuroprotective effect and a favorable safety profile.

Areas covered

This is a comprehensive review co

SUBMITTER: Kolb-Sobieraj C 

PROVIDER: S-EPMC4381916 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature